Reston, Va.The SNM Clinical Trials Network has announced that a prototype clinical PET oncology imaging simulatoror "phantom"has been successfully scanned and imaged at four imaging centers. SNM intends to deliver and scan the phantom at an additional 20 imaging centers by the end of September.
SNM's Clinical Trials Networkas part of its mission to ensure standardization and harmonization across multiple imaging sites participating in clinical trialsevaluates images produced by phantoms to ensure that molecular imaging centers are providing consistent and accurate images. Imaging consistency among sitesboth in the technology used and images producedis critical for ensuring quality imaging and quantitative data and is essential to meet Food and Drug Administration (FDA) requirements for investigational clinical trials.
"The community agrees that a lack of uniformity across imaging sites is a primary barrier to using imaging in clinical trials to facilitate drug development," said Michael Graham, Ph.D., M.D., co-chair of SNM's Clinical Trials Network and director of nuclear medicine at the University of Iowa Carver College of Medicine. "When pharmaceutical companies apply to FDA for approval of a new product, they must first demonstrate a certain level of disease detectability as evidenced by some imaging measurement. Many of the denials of new drugs are based on a rejection of data compiled from poor-quality images or images that don't appear to match those from another similar study."
Successfully scanning phantoms is one part of the overall process that the network will use to "validate" imaging sites for future clinical trials. Imaging of the PET phantoms, which contain a known quantity and distribution of radioactivity, will be used to evaluate each site's imaging capabilities both qualitatively and quantitatively and ensure standardization and compliance with defined protocols in order to ensure consistency across multiple centers in a single trial.
"The network's phantom program draws upon an SNM phantom imaging program that has been operational for over ten years. In addition, SNM maintains a group of experts who evaluate a center's image quality," said Paul E. Christian, chair of the Clinical Trials Network's Phantom Subcommittee and associate director of molecular imaging at the Huntsman Cancer Institute, University of Utah. "Based on these phantom images, experts can help imaging centers by recommending adjustments in the image acquisition parameters to produce images of a very high quality."
The first phantom in use is the oncology phantom (designed primarily to support investigational oncology clinical trials), which was scanned at each of four test sitesthe University of Utah, University of Iowa, University of Pennsylvania and Mayo Clinicusing a standard imaging protocol. To test the resolution of the imaging equipment at each site, the phantom contained multiple simulated tumors of different sizes. Physicians at each of the four sites were able to evaluate the images and identify all the tumors.
Based on this initial success with the oncology phantom, the network is expanding its phantom imaging program by providing other phantoms to qualified sites in the network's registry. In this regard, a cardiac phantom is beginning testing at the four initial sites, and a brain phantom prototype is being developed and is anticipated to be available by June to assist a pharmaceutical company with site imaging evaluation for an upcoming phase 3 clinical trial. These three phantoms will be on display at the MI Gateway in the exhibit hall during SNM's 56th Annual Meeting, June 13, Toronto, Canada.
|Contact: Amy Shaw|
Society of Nuclear Medicine